一开年，马斯克放出豪言：旗下脑机接口公司Neuralink将2026年大规模设备量产，引发全球股市上涨。 这边，被看作Neuralink最大对手的强脑科技，也迅速完成20亿元融资，并传出以保密形式递交港股IPO 申请。 而股民们最关心的A股，也没有被这股风口落下，即将迎来脑机接口第一股。 近日，脑机接口公司博睿康在上海证监局办理辅导备案登记，冲刺科创板上市。 博睿康核心团队来自清华大学，由红杉中国、百度风投等知名机构押注。 - 01 - 博睿康创始人胥红来生于1979年，本科、硕士、博士都就读于清华大学生物医学工程专业。硕博期间， 胥红来的导师是国际脑机接口学会唯一的国内理事高上凯。 2010 年，第一届中国脑机接口比赛上，胥红来看到，不管是高校代表队还是科研机构，手里的核心设 备清一色都是进口的。比赛结束后，中科院有位研究员给高上凯老师写了一封信。他在信中问，脑机接 口用到的设备全靠进口，以后还怎么产业化，成本又怎么降下来？ 2011年，胥红来拉上同系博士黄肖山创办博睿康。北京创业成本太高，团队把目光投向了常州 —— 这 里的科教城给政策、给孵化基金，连前期厂房都帮着协调。2011年11月，博睿康落地常州， ...

Company Overview - Brain-computer interface company, BoRuiKang Technology (Shanghai) Co., Ltd., has completed its IPO counseling registration on February 4, 2026, with CITIC Securities as the counseling broker, marking the official start of its Sci-Tech Innovation Board IPO process [1][2][3] - Established in November 2011, BoRuiKang's core team includes experts from Tsinghua University's Neural Engineering Laboratory and clinical neuroscience, focusing on the research, production, and technical services of brain-computer interface systems [3][4] - The company has developed products for clinical diagnosis and research education, including digital EEG machines and transcranial electrical stimulation systems, with some products already receiving medical device registration [3][4] Product Development - BoRuiKang's flagship product, the NEO wireless minimally invasive brain-computer interface system, is the world's first to use an epidural implant with fully wireless transmission design [3][4] - NEO employs a "semi-invasive" technique, implanting coin-sized electrodes beneath the skull but outside the dura mater, allowing proximity to neurons without direct contact, thus avoiding damage to neural tissue [4] - The NEO system has undergone successful clinical trials, with 32 patients having completed implantation across 11 hospitals, achieving a 100% success rate in primary clinical endpoints [4][5] Regulatory Progress - NEO is set to submit a Class III innovative medical device registration application to the National Medical Products Administration, potentially becoming the first marketed implantable brain-computer interface product in China [5] - The product's first version, NEO 1.0, is expected to be followed by a 2.0 version that will include additional features such as language decoding and small limb decoding [5] Financial Backing and Valuation - BoRuiKang has completed multiple rounds of financing, with notable investors including Sequoia China and Baidu Ventures, achieving a post-investment valuation of 3.5 to 4 billion yuan by the end of 2025 [5][6] - The company has raised a total of 1.2 million yuan in angel funding and 30 million yuan in Pre-A funding, among other financing rounds [5] Industry Context - The brain-computer interface industry is experiencing significant growth opportunities in China, supported by favorable policies and market conditions [9][10] - The Ministry of Industry and Information Technology and other departments have included brain-computer interfaces in key future industry cultivation, with projections indicating the market could exceed 120 billion yuan by 2040 [10]